Document Detail

Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris.
MedLine Citation:
PMID:  19468225     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The antianginal and anti-ischemic efficacy of ivabradine has been demonstrated in large-scale trials. Pooling trial data allowed for subpopulation analyses of ivabradine's antianginal efficacy. METHODS: Data on the frequency of angina attacks, short-acting nitrate consumption, and heart rate were pooled from 5 randomized trials in patients with stable angina pectoris receiving 5, 7.5, or 10 mg of ivabradine b.i.d. for 3 or 4 months. The subpopulations were defined according to age, sex, disease characteristics, and comorbidities (severity of angina, history of myocardial infarction, cerebrovascular disease, revascularization status, diabetes, asthma/chronic obstructive pulmonary disease, or peripheral vascular disease). RESULTS: Efficacy data were available for 2,425 patients (full analysis set), in whom ivabradine reduced the frequency of diary-based angina attacks by 59.4% and nitrate consumption by 53.7%. All subpopulations experienced 51-70% reductions in the frequency of angina attacks, with similar reductions for the other parameters studied. Ivabradine's efficacy was maintained in the presence of different comorbidities. In the safety set, ivabradine reduced heart rate by 14.5%. Ivabradine had a good safety and tolerability profile in all the subpopulations assessed. CONCLUSIONS: The antianginal efficacy of ivabradine was consistent across all the subpopulations analyzed, independent of the severity of angina and the presence of a comorbidity.
Michal Tendera; Jeffrey S Borer; Jean-Claude Tardif
Related Documents :
4054135 - Long-term follow-up after a controlled randomized post-myocardial infarction rehabilita...
7829785 - Development and evaluation of the seattle angina questionnaire: a new functional status...
24972675 - Physiologic or pathologic hypertrophy: how can we know?
432505 - Echocardiography in ischemic heart disease.
19602735 - Treating myocardial stunning randomly, with either propofol or isoflurane following tra...
17335135 - Does epirubicin affect left ventricular systolic performance in oncologic patients?
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2009-05-26
Journal Detail:
Title:  Cardiology     Volume:  114     ISSN:  1421-9751     ISO Abbreviation:  Cardiology     Publication Date:  2009  
Date Detail:
Created Date:  2009-09-04     Completed Date:  2009-12-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1266406     Medline TA:  Cardiology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  116-25     Citation Subset:  IM    
Copyright Information:
Copyright 2009 S. Karger AG, Basel.
3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Distribution
Aged, 80 and over
Angina Pectoris / diagnosis,  drug therapy*,  epidemiology,  therapy
Angioplasty, Transluminal, Percutaneous Coronary / methods
Benzazepines / administration & dosage*
Coronary Artery Bypass / methods
Cyclic Nucleotide-Gated Cation Channels / drug effects*
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Middle Aged
Randomized Controlled Trials as Topic
Recurrence / prevention & control
Risk Assessment
Severity of Illness Index
Sex Distribution
Survival Rate
Treatment Outcome
Reg. No./Substance:
0/Benzazepines; 0/Cyclic Nucleotide-Gated Cation Channels; 155974-00-8/ivabradine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quinolones with enhanced bactericidal activity induce autolysis in Streptococcus pneumoniae.
Next Document:  Laparoscopic removal of a foreign body in the pelvic cavity through one port using a flexible cholan...